马上提问，24小时在线专家与您一对一免费交流
在线咨询400-9691659
赤峰男科医院提供免费咨询、挂号服务
请输入您的电话号码，提前与医生一对一交流
艾尔健积极扩张$5.9亿购膀胱新药
专家热线：4006099869
2014年8月15日讯 /生物谷BIOON/ --为避开加拿大Valeant制药和潘兴广场（Pershing Square）530亿美元的敌意收购，艾尔健（Allergan）近日又有了新动作。日前，艾尔健宣布耗资5.875亿美元从Taris生物技术公司买进一种实验性膀胱药物Liris，该药目前处于II期临床，开发用于间质性膀胱炎（又名膀胱疼痛综合征，BPS）的治疗。Liris的工作原理是通过一个小的植入管，将抗炎药物利多卡因（lidocaine）持续递送至膀胱。该技术源自麻省理工学院。
该笔交易，将用于支持艾尔健泌尿外科研发管线，同时也建立在该公司BOTOX（保妥适）于2013年获批用于膀胱过度活动症（OAB）的成功基础之上。今年1月，在摩根大通医疗大会上，艾尔健CEO David Pyott在接受FierceBiotech采访时表示，将拿出100亿美元专门用于收购。
当然，这是在Valeant制药和潘兴广场提出一系列敌意收购之前的计划，这场持续长达一个月的拉锯战，导致艾尔健不得不对其研发战略进行重新评估。此外，在敌意收购者对其臃肿预算的指责声中，艾尔健已宣布计划裁员1500人，约占员工总数的13%，同时也计划削减对早期研发的投入。
此前，Valeant制药与潘兴广场合作，要求艾尔健召开股东特别大会，意图踢出6位董事会成员，并迫使艾尔健并接受其敌意收购。目前，这场拉锯战仍处于僵局。
至于Taris公司，出售Liris后将使公司能够专注于膀胱癌和膀胱过度活动症（OAB）领域的临床前资产。此外，Taris也正在与阿斯利康（AZN）合作，推进一个单独的膀胱癌项目。
艾尔健以肉毒杆菌药物Botox闻名。根据Valeant，收购艾尔健将在眼科、皮肤科及美学领域缔造无与伦比的产品组合，同时将产生显著的成本及收入协同效应。（生物谷Bioon.com）
英文原文：Allergan bets up to $588M on Taris' bladder candidate
Amid its fight to stave off a hostile takeover, Botox maker Allergan ($AGN) is making a buy of its own, trading up to $587.5 million for a midstage bladder drug from the biotech Taris.
Under the deal, Allergan gets worldwide rights to Liris, a Phase II drug-device combo designed to treat interstitial cystitis, or painful bladder syndrome. The company paid $67.5 million up front and is on the line for another $295 million in development milestones and as much as $225 million tied to commercial performance.
Liris works by continuously delivering the anti-inflammatory drug lidocaine through a small implanted tube feeding directly into the bladder. The technology stems from the labs of MIT's prolific entrepreneurs Michael Cima and Robert Langer, and its promise was enough to sway Polaris Venture Partners, Third Rock Ventures, Flybridge Capital Partners and Flagship Ventures, all of which participated in Taris' $12.5 million E round last year.
For Allergan, the deal bolsters its pipeline in urology and builds off of the company's success in getting Botox approved as a second-line treatment for overactive bladder last year, CEO David Pyott said. The chief executive has long had his eye on expanding Allergan's prospects through M&A, telling FierceBiotech at January's J.P. Morgan Healthcare Conference that he had a $10 billion purse earmarked for takeovers.
Of course, that was before Valeant Pharmaceuticals ($VRX) came calling with a series of hostile offers, sparking a months-long back and forth that has led Allergan to re-evaluate its approach to R&D. Amid its suitor's accusations of bloated budgeting, Allergan has announced plans to cut 13% of its workforce--about 1,500 employees--and curtail its commitment to early-stage research. The two sides remain at an impasse, with Valeant and co-agitator Pershing Square Capital Management working to force a shareholder meeting and get Allergan to take their $48.7 billion offer.
As for Taris, selling off its top prospect will leave the company to focus on its preclinical assets in bladder cancer and overactive bladder, CEO Purnanand Sarma said. The biotech is also working alongside AstraZeneca ($AZN) on a separate bladder cancer program, pursuing multiple candidates under a 2013 agreement.
赤峰市红山区钢铁街中段88号军分区十字路口
专家热线：0476-5877999。400免费电话：4006099869
门诊时间：8:00—18:00 版权所有：赤峰九洲医院
